Serum Prognostic Biomarkers in Head and Neck Cancer Patients

Overview

Journal Laryngoscope

Specialty Otorhinolaryngology

Date 2013 Dec 19

PMID 24347532

Citations 4

Authors

Ho-Sheng Lin

Fauzia Siddiq

Harvinder S Talwar

Wei Chen

Calin Voichita

Sorin Draghici

Gerald Jeyapalan

Madhumita Chatterjee

Andrew Fribley

George H Yoo

Seema Sethi

Harold Kim

Ammar Sukari

Adam J Folbe

Michael A Tainsky

Affiliations

Soon will be listed here.

Abstract

Objectives/hypothesis: A reliable estimate of survival is important as it may impact treatment choice. The objective of this study is to identify serum autoantibody biomarkers that can be used to improve prognostication for patients affected with head and neck squamous cell carcinoma (HNSCC).

Study Design: Prospective cohort study.

Methods: A panel of 130 serum biomarkers, previously selected for cancer detection using microarray-based serological profiling and specialized bioinformatics, were evaluated for their potential as prognostic biomarkers in a cohort of 119 HNSCC patients followed for up to 12.7 years. A biomarker was considered positive if its reactivity to the particular patient's serum was greater than one standard deviation above the mean reactivity to sera from the other 118 patients, using a leave-one-out cross-validation model. Survival curves were estimated according to the Kaplan-Meier method, and statistically significant differences in survival were examined using the log rank test. Independent prognostic biomarkers were identified following analysis using multivariate Cox proportional hazards models.

Results: Poor overall survival was associated with African Americans (hazard ratio [HR] for death = 2.61; 95% confidence interval [CI]: 1.58-4.33; P = .000), advanced stage (HR = 2.79; 95% CI: 1.40-5.57; P = .004), and recurrent disease (HR = 6.66; 95% CI: 2.54-17.44; P = .000). On multivariable Cox analysis adjusted for covariates (race and stage), six of the 130 markers evaluated were found to be independent prognosticators of overall survival.

Conclusions: The results shown here are promising and demonstrate the potential use of serum biomarkers for prognostication in HNSCC patients. Further clinical trials to include larger samples of patients across multiple centers may be warranted.

Citing Articles

Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review.

Uz U, Eskiizmir G Clin Exp Otorhinolaryngol. 2021; 14(1):50-60.

PMID: 33587847 PMC: 7904429. DOI: 10.21053/ceo.2019.00906.

Survivin expression and impact on head and neck cancer outcomes.

Khan S, Burke M, Zhu F, Yang D, Dubyk C, Mehra R Oral Oncol. 2020; 112:105049.

PMID: 33221541 PMC: 10916757. DOI: 10.1016/j.oraloncology.2020.105049.

Profiling of Mitochondrial DNA Heteroplasmy in a Prospective Oral Squamous Cell Carcinoma Study.

Fendt L, Fazzini F, Weissensteiner H, Bruckmoser E, Schonherr S, Schafer G Cancers (Basel). 2020; 12(7).

PMID: 32708892 PMC: 7409097. DOI: 10.3390/cancers12071933.

Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue.

Boldrup L, Troiano G, Gu X, Coates P, Fahraeus R, Wilms T Oncotarget. 2017; 8(61):103437-103448.

PMID: 29262574 PMC: 5732740. DOI: 10.18632/oncotarget.21402.

References

Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J . p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer. 1998; 78(8):1084-90. PMC: 2063151. DOI: 10.1038/bjc.1998.632. View

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

Ansari-Lari M, Oeltjen J, Schwartz S, Zhang Z, Muzny D, Lu J . Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res. 1998; 8(1):29-40. View

David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J . Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem. 2002; 277(20):18084-90. DOI: 10.1074/jbc.M102285200. View

Rimoldi D, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D . Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000; 165(12):7253-61. DOI: 10.4049/jimmunol.165.12.7253. View

Chatterjee M, Ionan A, Draghici S, Tainsky M . Epitomics: global profiling of immune response to disease using protein microarrays. OMICS. 2007; 10(4):499-506. DOI: 10.1089/omi.2006.10.499. View

Chen Y, Scanlan M, Sahin U, Tureci O, Gure A, Tsang S . A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94(5):1914-8. PMC: 20017. DOI: 10.1073/pnas.94.5.1914. View

Diesinger I, Bauer C, Brass N, Schaefers H, Comtesse N, Sybrecht G . Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. Int J Cancer. 2002; 102(4):372-8. DOI: 10.1002/ijc.10714. View

10.

Psyrri A, Yu Z, Weinberger P, Sasaki C, Haffty B, Camp R . Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005; 11(16):5856-62. DOI: 10.1158/1078-0432.CCR-05-0420. View

11.

Bosch F, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A . Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer. 2004; 111(4):530-8. DOI: 10.1002/ijc.11698. View

12.

Lin H, Talwar H, Tarca A, Ionan A, Chatterjee M, Ye B . Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(11):2396-405. PMC: 2575765. DOI: 10.1158/1055-9965.EPI-07-0318. View

13.

Aebersold D, Froehlich S, Jonczy M, Beer K, Laissue J, Greiner R . Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol. 2002; 63(3):275-83. DOI: 10.1016/s0167-8140(02)00131-7. View

14.

Shoushtari A, Rahimi N, Schlesinger D, Read P . Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States. Cancer. 2009; 116(2):514-9. DOI: 10.1002/cncr.24752. View

15.

Wang R, Parkhurst M, Kawakami Y, Robbins P, Rosenberg S . Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 1996; 183(3):1131-40. PMC: 2192321. DOI: 10.1084/jem.183.3.1131. View

16.

Scanlan M, Chen Y, Williamson B, Gure A, STOCKERT E, Gordan J . Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998; 76(5):652-8. DOI: 10.1002/(sici)1097-0215(19980529)76:5<652::aid-ijc7>3.0.co;2-p. View

17.

Soussi T . p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60(7):1777-88. View

18.

Akin D, Lu M, Lu S, Kendall S, Rundegren J, Arnold R . Bactericidal activity of different forms of lactoferrin. Adv Exp Med Biol. 1994; 357:61-70. DOI: 10.1007/978-1-4615-2548-6_7. View

19.

Geysen H, Rodda S, Mason T . A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol. 1986; 23(7):709-15. DOI: 10.1016/0161-5890(86)90081-7. View

20.

Disis M, Calenoff E, McLaughlin G, Murphy A, Chen W, Groner B . Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994; 54(1):16-20. View